Peter Heald, MD
DownloadHi-Res Photo
Cards
Appointments
Dermatology
Primary
Contact Info
About
Titles
Professor Emeritus of Dermatology
Biography
Dr. Heald has defined the role of an academic referral dermatologist by being a physician in a position to improve the care of patients well beyond his immediate control. Education has been the primary tool of this trade within the fields of cutaneous lymphoma and complex medical dermatology. His educational projects have involved physician extenders, medical students, residents and in the continuing education of physicians.
Appointments
Education & Training
- Research Fellow
- University of Pennsylvania (1986)
- Resident
- Duke University Medical Center (1984)
- Resident
- Duke University Medical Center (1982)
- Intern
- Duke University Medical Center (1980)
- MD
- Duke University (1978)
Board Certifications
Clinical & Lab Dermatopathological Immunology
- Certification Organization
- AB of Dermatology
- Original Certification Date
- 1987
Dermatology
- Certification Organization
- AB of Dermatology
- Original Certification Date
- 1984
Internal Medicine
- Certification Organization
- AB of Internal Medicine
- Original Certification Date
- 1982
Research
Research at a Glance
Yale Co-Authors
Frequent collaborators of Peter Heald's published research.
Publications Timeline
A big-picture view of Peter Heald's research output by year.
Michael Girardi, MD, FAAD
Frank Bia, MD, MPH
Richard L Edelson, MD
5Publications
1,331Citations
Publications
2008
FDG-PET/CT for the Evaluation of Response to Therapy of Cutaneous T-cell Lymphoma to Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) in a Phase II Trial
Kuo PH, Carlson KR, Christensen I, Girardi M, Heald PW. FDG-PET/CT for the Evaluation of Response to Therapy of Cutaneous T-cell Lymphoma to Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) in a Phase II Trial. Molecular Imaging And Biology 2008, 10: 306-314. PMID: 18665425, DOI: 10.1007/s11307-008-0161-4.Peer-Reviewed Original ResearchCitationsMeSH Keywords and ConceptsConceptsCutaneous T-cell lymphomaFDG PET/CTPhase II trialParticular positron emission tomographyT-cell lymphomaII trialNodal diseaseInitial PET/CT scanPET/CT scansEarly clinical trialsEvaluation of responseHistone deacetylase inhibitorsAlters gene transcriptionPositron emission tomographyFDG uptakeCutaneous lesionsFDG-PETPrognostic valueFuture trialsClinical trialsConclusionFurther studiesCell lymphomaCT scanDeacetylase inhibitorsHDAC inhibitorsFDG-PET/CT in the Evaluation of Cutaneous T-Cell Lymphoma
Kuo PH, McClennan BL, Carlson K, Wilson LD, Edelson RL, Heald PW, Girardi M. FDG-PET/CT in the Evaluation of Cutaneous T-Cell Lymphoma. Molecular Imaging And Biology 2008, 10: 74-81. PMID: 18196347, DOI: 10.1007/s11307-007-0127-y.Peer-Reviewed Original ResearchCitationsMeSH Keywords and ConceptsConceptsCutaneous T-cell lymphomaPET/CTT-cell lymphomaFDG uptakeD-glucose positron emission tomography/FDG PET/CTPositron emission tomography/PET/CT scansComprehensive case seriesTomography (CT) of patientsMonitoring of responseMalignant adenopathyActive diseaseAdvanced diseaseCutaneous examinationVisceral diseaseVisceral involvementLymph nodesCase seriesCutaneous lesionsPhysical examinationThicker tumorsTomography/Physical examIndividual patients'Coral reef' psoriasis: a marker of resistance to topical treatment.
Feldman SR, Brown KL, Heald P. 'Coral reef' psoriasis: a marker of resistance to topical treatment. The Journal Of Dermatological Treatment 2008, 19: 257-8. PMID: 18608734, DOI: 10.1080/09546630802032611.Peer-Reviewed Original Research
2007
Revisions to the staging and classification of mycosis fungoides and Sézary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC)
Olsen E, Vonderheid E, Pimpinelli N, Willemze R, Kim Y, Knobler R, Zackheim H, Duvic M, Estrach T, Lamberg S, Wood G, Dummer R, Ranki A, Burg G, Heald P, Pittelkow M, Bernengo M, Sterry W, Laroche L, Trautinger F, Whittaker S, for the ISCL/EORTC. Revisions to the staging and classification of mycosis fungoides and Sézary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood 2007, 110: 1713-1722. PMID: 17540844, DOI: 10.1182/blood-2007-03-055749.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsCutaneous T-cell lymphomaSézary syndromeMycosis fungoidesCutaneous lymphomasCutaneous Lymphoma Task ForceT-cell lymphomaPotential prognostic significanceStandardized clinical trialsClinical characteristicsStaging procedurePrognostic significanceTreatment of cancerStaging systemTumor cell biologyClinical trialsEuropean OrganizationLymphomaOriginal guidelinesFungoidesSyndromeInternational SocietyDiagnostic techniquesTask ForceEORTCPrognosis
1993
Cutaneous Cryptococcosis in a Patient with Cutaneous T Cell Lymphoma Receiving Therapy with Photopheresis and Methotrexate
Frieden T, Bia F, Heald P, Eisen R, Patterson T, Edelson R. Cutaneous Cryptococcosis in a Patient with Cutaneous T Cell Lymphoma Receiving Therapy with Photopheresis and Methotrexate. Clinical Infectious Diseases 1993, 17: 776-778. PMID: 8268362, DOI: 10.1093/clinids/17.4.776.Peer-Reviewed Original ResearchCitationsMeSH Keywords and Concepts
Get In Touch
Contacts
Email